Acumen Pharmaceuticals (ABOS) investor relations material

Executive summary

• Advanced sabirnetug through Phase II ALTITUDE-ad trial, completing enrollment in March 2025, with topline results expected late 2026 and high participant conversion to open-label extension.

• Enhanced Brain Delivery (EBD) program progressing, with imminent candidate selection, IND filing targeted for mid-2027, and collaboration with JCR Pharmaceuticals for blood-brain barrier-penetrating technology.

• Closed a $35.75 million private placement in March 2026 to support the EBD program and general operations.

• Strong physician and KOL interest in sabirnetug's differentiated mechanism targeting Abeta oligomers.

• Fast Track designation granted by FDA for sabirnetug in early Alzheimer's disease.

Financial highlights

• Ended Q1 2026 with $128.4 million in cash and marketable securities, supporting operations into early 2027.

• R&D expenses were $16.5 million for Q1 2026, down year-over-year due to lower manufacturing and CRO costs.

• G&A expenses were $4.7 million for Q1 2026, down from prior year due to reduced legal, accounting, consulting, and insurance costs.

• Net loss for Q1 2026 was $20.7 million, narrowed from $28.8 million in Q1 2025.

• Accumulated deficit reached $467.2 million as of March 31, 2026.

Outlook and guidance

• Cash and marketable securities expected to fund operations into early 2027, but substantial doubt exists about ability to continue as a going concern without additional funding.

• ALTITUDE-ad Phase II topline results anticipated late 2026, with primary and secondary endpoints including efficacy, safety, and biomarkers.

• EBD program candidate selection expected in Q2 2026, with IND filing planned for mid-2027.

• Expenses and operating losses expected to increase as clinical and preclinical programs advance.